CooperVision lens reduces progression of myopia

CooperVision 1-day soft contact lens reduced the rate of progression of juvenile-onset myopia

Adolescents who are myopic (nearsighted) typically have “progressive myopia”


Stockwinners offering sock research, wining stock and option picks since 1998

The British Contact Lens Association Clinical Conference ended on Sunday in Liverpool England. Among companies presenting at the conference were Cooper Companies.

Cooper Companies subsidiary CooperVision announced Saturday that “a pioneering contact lens therapy has considerable potential to impact the rising prevalence of myopia in children, according to highly-anticipated study outcomes presented today at the British Contact Lens Association Clinical Conference.”

At the conference, CooperVision reviewed three-year results from the clinical trial assessing a specially-designed, dual-focus myopia control 1-day soft contact lens in reducing the rate of progression of juvenile-onset myopia.

Adolescents who are myopic (nearsighted) typically have “progressive myopia” — that is, their nearsightedness becomes progressively greater over time. If left uncontrolled, myopia results in a higher incidence of complications such as retinal tears and detachments, glaucoma, cataracts, and a reduced quality of life.

Three-year findings indicated that use of the dual-focus contact lens was effective in slowing myopia progression 59% as measured by mean cycloplegic spherical equivalent and 52% as measured by mean axial elongation of the eye when compared to the children in the control group wearing a single vision 1-day contact lens.

Three-year results indicated the dual focus lens was well accepted by children, and did not affect their daily activities. Children in both the test and control groups had a higher satisfaction with contact lenses over spectacles.

Parents of study participants also had a very positive response, noting their children could mostly manage their lens wear independently.

“No other prospective randomized controlled study has offered conclusive data for such a high degree of continued efficacy in myopia management using a 1-day soft contact lens over three years,” the company remarked.

COO closed at $237.43. Shares have a 52-week trading range of $158.73 to $243.88.

To read stories similar to this, sign up for a free trial membership to Stockwinners; be sure to check the Market Radar section.

The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility.



Leave a Reply

Your email address will not be published. Required fields are marked *